Unlocking Growth Opportunities in Autoimmune Diseases

Rheumatoid Arthritis
- Clinical development planning for a novel small molecule therapy
- Conjoint analysis with rheumatologists to determine positioning and revenue potential of a new oral therapy
- Evaluation of the impact of biosimilars on an RA franchise
- Incorporation of predictive diagnostics as a lifecycle management tool
- Due diligence of a novel lymphocyte proliferation antagonist
- Competitive analysis to evaluate a potential lead indication for a transdermal product reformulation
- Market opportunity and forecast model for a manufacturer to navigate the biosimilar landscape

Multiple Sclerosis
- Identification and prioritization of strategic initiatives for global neuro-immunology franchise
- Market assessment of RNAi-based technology for immune indications
- Elucidation of neurologist and patient unmet needs through clinic visits and on-site interviews
- Development costs and revenue projections for prognostic and predictive biomarkers
- US and EU commercialization strategy for biosimilar interferon
- Launch plan and post-marketing trial design
- Portfolio prioritization for an MRI imaging company

Psoriasis
- Market evaluation and development path for a compound with a novel mechanism of action
- Strategic commercialization plan to drive partnership discussions
- Label expansion opportunities for an approved biologic
- Operational issues analysis of drug delivery methods in US and EU physicians’ offices
- Portfolio prioritization to optimize a development-stage company’s proprietary technology
- Lifecycle management strategy taking into account the development of biomarkers to predict patient response
- Competitive landscape analysis to guide development of a novel antibody technology

IBD, Lupus and Others
- Evaluation of IBD as an expansion opportunity for a multinational company’s autoimmune franchise
- Development of a dynamic mixed prevalence/incidence global forecasting model for Crohn’s disease International market opportunity for a novel biologic treatment for SLE and Sjogren’s syndrome
- Forecast model for stem cell technology in autoimmune indications
- Lead indication evaluation for locally delivered glycoconjugates
- Evaluation and forecast of the market for systemic lupus erythematosus and lupus nephritis
- Clinical development planning for a novel UC biologic therapy